Literature DB >> 11329056

Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice.

S Maier1, C Tertilt, N Chambron, K Gerauer, N Hüser, C D Heidecke, K Pfeffer.   

Abstract

Successful transplantation of allogeneic organs is an important objective in modern medicine. However, sophisticated immune defense mechanisms, primarily evolved to combat infections, often work against medical transplantation. To investigate the roles of natural and adaptive immune responses in transplant rejection, we functionally inactivated key effector systems of the innate (NK cells) and the adaptive immune system (CD28-mediated costimulation of T cells) in mice. Neither of these interventions alone led to acceptance of allogeneic vascularized cardiac grafts. In contrast, inhibition of NK-receptor-bearing cells combined with CD28-costimulation blockade established long-term graft acceptance. These results indicate a concerted interplay between innate and adaptive immune surveillance for graft rejection. Thus we suggest that inactivation of NK-receptor-bearing cells could be a new strategy for successful survival of solid-organ transplants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329056     DOI: 10.1038/87880

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  63 in total

Review 1.  An overview on non-T cell pathways in transplant rejection and tolerance.

Authors:  Wentao Liu; Xian C Li
Journal:  Curr Opin Organ Transplant       Date:  2010-08       Impact factor: 2.640

Review 2.  Immunology in the Clinic Review Series; focus on host responses: invariant natural killer T cell activation following transplantation.

Authors:  J-P Jukes; N D Jones
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  CD28-mediated costimulation impacts on the differentiation of DC vaccination-induced T cell responses.

Authors:  H Voigt; D Schrama; A O Eggert; C S Vetter; K Müller-Blech; H M Reichardt; M H Andersen; J C Becker; F Lühder
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses.

Authors:  Hideaki Obara; Kazuhito Nagasaki; Christine L Hsieh; Yasuhiro Ogura; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Am J Transplant       Date:  2005-09       Impact factor: 8.086

Review 5.  Mechanisms of chronic rejection in cardiothoracic transplantation.

Authors:  Matthew J Weiss; Joren C Madsen; Bruce R Rosengard; James S Allan
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  The innate immune system in allograft rejection and tolerance.

Authors:  David F LaRosa; Adeeb H Rahman; Laurence A Turka
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

7.  Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus.

Authors:  Adrian Erlebacher; Daniela Vencato; Kelly A Price; Dorothy Zhang; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

Review 8.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

9.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Authors:  Camilla Jandus; Kayluz Frias Boligan; Obinna Chijioke; He Liu; Meike Dahlhaus; Thomas Démoulins; Christoph Schneider; Marc Wehrli; Robert E Hunger; Gabriela M Baerlocher; Hans-Uwe Simon; Pedro Romero; Christian Münz; Stephan von Gunten
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

10.  Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal peritonitis.

Authors:  Markus Entleutner; Tobias Traeger; Alexandra Westerholt; Bernhard Holzmann; Albrecht Stier; Klaus Pfeffer; Stefan Maier; Claus-Dieter Heidecke
Journal:  Int J Colorectal Dis       Date:  2005-03-09       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.